What is Cramer?
Cramer operates at the intersection of industrial design and medical-grade utility, providing seating solutions engineered for the rigorous demands of laboratories, hospitals, and research facilities. By integrating patented technologies such as the Rhino Plus system, the company addresses the critical need for chemical resistance and ergonomic support in high-stakes environments. Their product portfolio, which includes the Citrus and Rhino series, emphasizes a balance between modern aesthetics and functional durability, ensuring that medical professionals maintain comfort during extended shifts while adhering to strict sanitation standards. The company's focus on intuitive, adaptive seating—exemplified by their Flex Function technology—positions them as a critical supplier in the evolving landscape of modern healthcare facility design.
How much funding has Cramer raised?
Cramer has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in Cramer
PPP
Public-Private Partnership
What's next for Cramer?
Following this late-stage financing, Cramer is expected to prioritize the scaling of its manufacturing capabilities and the expansion of its distribution network across global Med-Tech markets. The infusion of capital will likely support further research and development into advanced polyurethane materials and ergonomic innovations, reinforcing their competitive advantage in the clinical seating sector. As the demand for high-performance, easy-to-sanitize furniture continues to rise in response to global health standards, Cramer is strategically aligned to capture additional market share by leveraging its reputation for engineering excellence and technical reliability.
See full Cramer company page
